Thursday, December 02, 2021 7:25:53 PM
On August 31, 2021, the board of directors, by consent entered a Stock Purchase agreement with Vyome Therapeutics,
Inc., to sell to Vyome Therapeutics, Inc., 986,919 of the 996,919 of the company’s A-1 preferred shares. On the date of
closing, Vyome Therapeutics, Inc., purchased 996,919 shares of Livechain, Inc.’s, A-1 proffered stock, assuming
70.08% of the companies issued and outstanding shares. At the time of transfer, Venkat Nelabhotla, Chief Executive
Officer and Director of Vyome Therapeutics, Inc., also became Chief Executive Officer and Director of Livechain, Inc.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM